Is a complete GLUE research report available?

No complete published report is available for Monte Rosa Therapeutics, Inc. (GLUE) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · USD

$21.6

-0.48 (-2.2%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first GLUE analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	1.8B
Revenue (ttm)	43M
Net income (ttm)	-130M
EPS (ttm)	-$1.50
Shares out	84.5M
Volume	1,233,803
Beta	1.56
Price target	$34.8	+61.5%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 43M
Net income (ttm): -130M
EPS (ttm): -$1.50
Market cap: 1.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All GLUE indicators

Market & fundamental data

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001826457
Company name	Monte Rosa Therapeutics, Inc.
Country	United States
Country code	US
Cusip	61225M102
Employees	187
Employees Change	45%
Employees Change Percent	31.69
Enterprise value	$1.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-24
Isin	US61225M1027
Last refreshed	2026-07-30
Market cap	$1.8B
Market cap category	Small-Cap
Price	$21.56
Price currency	USD
Rev Per Employee	229,695.19x
Sector	Healthcare
Sector PE	45.63
Sector PE Fwd	24.38
Sic	2836
Symbol	GLUE
Website	https://www.monterosatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-7.14%
EV Sales Forward	26.99x
EV/Sales	27.8x
FCF yield	-1.08%
P/B ratio	3.56x
P/S ratio	42.4x
PS Forward	41.16x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-345.21%
EBITDA Margin	-325.8%
Gross margin	-238.54%
Gross Profit	$-102.5M
Net Income	$-130M
Net Income Growth Years	2%
Pretax Margin	-307.04%
Profit Per Employee	$-695,262
ROA	-16.41
Roa5y	-18.15
ROCE	-22.28
ROE	-32.62
Roe5y	-37.72
ROIC	-21.11

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	288.83%
Cagr3y	44.93%
Cagr5y	-1.28%
EPS Growth Years	2
Revenue Growth	-73.07x
Revenue Growth Q	-95.04x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.08
Assets	$736.4M
Cash	$666.2M
Current Assets	$677.5M
Current Liabilities	$71M
Debt	$39.1M
Debt Equity	$0.07
Equity	$521.9M
Liabilities	$214.5M
Long Term Assets	$58.9M
Long Term Liabilities	$143.5M
Net Cash	$627.2M
Net Cash By Market Cap	$34.43
Net Cash Growth	120.67%
Net Debt Equity	$-1.2
Tangible Book Value	$521.9M
Tangible Book Value Per Share	$6.19
WACC	12.57

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.54
Net Working Capital	$-55.2M
Quick ratio	9.44
Working Capital	$606.5M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.92%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	288.47%
200-day SMA	18.07
3Y total return	204.52%
50-day SMA	20.71
50-day SMA vs 200-day SMA	50over200
5Y total return	-6.26%
All Time High	45.56
All Time High Change	-52.68%
All Time High Date	2021-09-07
All Time Low	2.44
All Time Low Change	783.61%
All Time Low Date	2023-10-25
ATR	1.46
Beta	1.56
Beta1y	2.23
Beta2y	1.77
Ch YTD	37.5
High	22.72
High52	25.77
High52 Date	2026-01-08
High52ch	-16.34%
Low	21.16
Low52	4.12
Low52 Date	2025-08-08
Low52ch	423.3%
Ma50ch	4.11%
Price vs 200-day SMA	19.33%
RSI	44.95
RSI Monthly	65.6
RSI Weekly	56.97
Sharpe ratio	1.83x
Sortino ratio	4.22
Total Return	-9.92%
Tr YTD	37.5
Tr1m	-3.28%
Tr1w	-9.37%
Tr3m	13.41%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	6
Analyst Price Target Top	$33
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.34
Earnings Revenue Estimate	15,447,944x
Earnings Revenue Estimate Growth	-33.4x
Operating Income	$-148.3M
Operating margin	-345.2
Price target	$34.83
Price Target Change	$61.55
Price Target Change Top	$53.06

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	54,015,339%
Float Percent	63.94%
Shares Insiders	0.54%
Shares Institutions	77.72%
Shares Out	84,479,418
Shares Qo Q	16.76%
Shares Yo Y	9.92%
Short Float	31.83%
Short Ratio	9.95
Short Shares	20.35

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-39.2M
Adjusted OCF	-34,191,000
Average Volume	1,164,562.75x
Bv Per Share	6.19
CAPEX	$-5M
Ch1m	-3.28
Ch1w	-9.37
Ch1y	288.5
Ch3m	13.41
Ch3y	204.5
Ch5y	-6.26
Ch6m	2.04
Change	-2.18%
Change From Open	-3.01
Close	22.04
Days Gap	0.86
Depreciation Amortization	8,337,000
Dollar Volume	26,600,792.7
Earnings Date	2026-08-07
Earnings Time	bmo
EBIT	$-148.3M
EBITDA	$-139.9M
EPS	$-1.5
F Score	2
FCF	$-19.7M
FCF EV Yield	-1.65x
FCF Per Share	$-0.23
Financing CF	358,672,000
Fiscal Year End	December
Founded	2,019
Income Tax	$-1.9M
Investing CF	-262,601,000
Ipr	13.47
Iprfo	-2
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-17
Ma150	19.47
Ma150ch	10.74%
Ma20	23.35
Ma20ch	-7.65%
Net CF	81,396,000
Next Earnings Date	2026-08-10
Open	22.23
Optionable	Yes
Position In Range	25.64
Post Close	21.56
Postmarket Change Percent	0.65
Postmarket Price	$21.7
Ppne	53,102,000
Price Date	2026-07-29
Ptbv Ratio	3.49
Relative Volume	1.06x
Revenue	42,953,000x
SBC By Revenue	45.44x
Share Based Comp	19,516,000
Tax By Revenue	-4.35x
Tr6m	2.04%
Us State	Massachusetts
Volume	1,233,803
Z Score	1.42

Monte Rosa Therapeutics, Inc. (GLUE)

Coverage state: Market snapshot only — no published research

Generate the first GLUE analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · GLUE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GLUE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on GLUE

Frequently asked questions